Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
MarketBuzzGet your daily dose of market buzz with MarketBuzz! We cut through the noise, delivering clear, concise analysis of all things stocks - red alerts, big gainers, top losers, trending tickers, headline headlines, pre-market moves, after-hours action, and the overall market sentiment.
Dec 07 2024It's been an electrifying week in the markets, and several stocks have been lighting up screens and dominating conversations in trading circles. From breakthrough trial results to massive earnings beats, these stocks are making waves—and you’ll want to keep your eyes on them. Let’s dive into the Hottest Stocks of the Week, featuring TARA, PSQH, SOUN, CCRN, and CRDO.
This week, TARA transitioned from a whisper to a roar. Featured on Benzinga’s "Stock Whisper Index," Protara Therapeutics was already capturing the attention of savvy investors before its breakout moment. But what really ignited the stock was the positive results from its Phase 2 ADVANCED-2 trial for TARA-002, a promising bladder cancer therapy targeting NMIBC (Non-Muscle Invasive Bladder Cancer).
The stock skyrocketed over 100% on Thursday after the company’s announcement, proving that biotech breakthroughs still hold massive upside potential. With pre-market activity showing strong momentum and a surge in volume, TARA is officially on the radar of institutional and retail investors alike.
Biotech stocks can be volatile, but a mid-stage trial success puts TARA-002 closer to commercialization. If the momentum continues, TARA could become one of the biggest turnaround stories of the year.
If drama was a stock, it would be PSQH this week. The microcap commerce and payments company made headlines after Donald Trump Jr. joined the board of directors, sending shares soaring a jaw-dropping 270% in a single session.
But with great surges come great corrections. News of a 7.8 million share offering sent the stock down over 30% pre-market the next day, reminding investors that microcaps are not for the faint of heart. Despite the dip, PSQH remains a high-risk, high-reward play, and Trump Jr.’s involvement has injected a new level of interest into this formerly under-the-radar stock.
For aggressive traders, volatility equals opportunity. Keep PSQH on your watchlist if you’re willing to stomach the swings.
Artificial intelligence stocks are red-hot, and SoundHound AI (SOUN) is leading the charge. The stock has surged 564% year-to-date, and this week alone saw another round of explosive gains. Why? The company announced the deployment of its voice AI Smart Ordering system at all 130 Torchy’s Tacos locations, showcasing real-world adoption of its cutting-edge technology.
Investors are buzzing about SoundHound’s ability to carve out a niche in the AI space, and the stock’s 30% surge on Thursday only solidified its status as a market favorite. With momentum firmly intact, the big question is whether SOUN can sustain its meteoric rise.
AI is a long-term growth theme, and SOUN is proving it has the chops to capitalize on this transformative trend. For traders, the volatility is thrilling. For investors, the growth potential is undeniable.
Mergers and acquisitions are always exciting, and Cross Country Healthcare (CCRN) became the latest beneficiary. Shares rocketed after the company announced it would be acquired by Aya Healthcare for $18.61 per share in an all-cash deal, representing a 67% premium to its previous closing price.
For CCRN shareholders, this is a win-win. For traders, it’s a reminder that buyout rumors and announcements can be lucrative opportunities.
With the healthcare sector consolidating, keep an eye on similar names that could benefit from M&A activity. The premium paid for CCRN shows there’s still appetite for strategic deals.
AI isn’t just about flashy software—it’s also about the infrastructure powering it. Enter Credo Technology Group (CRDO), which blew away expectations with its latest earnings report. The company reported non-GAAP EPS of $0.07, beating estimates by $0.02, and revenue of $72.03M, beating by $5.22M.
The real excitement came from management bullish guidance, citing an AI-driven inflection point and new cloud customers as key growth catalysts. Wall Street is taking notice
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the article should not be considered as investment advice or marketing, and it does not take into account the personal data and requirements of any individual. It is not a substitute for the reader's own judgment, and it should not be considered as advice or recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity and Stay Ahead: Stock Market Updates, Expert Analysis, and Future Predictions
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
In-Depth Stock Analysis
Stock Sentiment Visualization
Daily Alerts for Stock Market Insights
Disclaimer:
Past performance, whether actual or indicated by historical tests, is not indicative of future success. Results are based on strategies not previously available to investors and may not reflect actual investor returns.
Readiness and Sentiment Indicators, as well as the total score, are calculated using historical data and assumptions integral to the model, and they may be subject to losses. Active trading may not be suitable for individuals with limited resources, investment experience, or a low-risk tolerance. Your capital is at risk.
Please note that StocksRunner and its affiliates ("TS") do not offer, solicit, or endorse securities, derivatives, investment advice, or strategies of any kind. This information is for illustrative purposes only. Do not rely on it for investment decisions.
Before making any investment, we recommend considering its appropriateness for your situation and seeking relevant financial, tax, and legal advice.
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
FIND US ON
Gain the edge that thousands of savvy investors rely on! Subscribe now for premium insights and stay one step ahead in the stock market. Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
